# A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects

> **NCT01911741** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Europe B.V.** · enrollment: 55 (actual)

## Conditions studied

- Healthy Subjects
- Castration Resistant Prostate Cancer (CRPC)
- Relative Bioavailability
- MDV3100

## Interventions

- **DRUG:** MDV3100

## Key facts

- **NCT ID:** NCT01911741
- **Lead sponsor:** Astellas Pharma Europe B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2013-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01911741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01911741, "A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01911741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*